Navigation Links
Telescoping Cool TROM

ProductsTelescoping Cool TROM
Company DJO Incorporated
Item Telescoping Cool TROM
Features 
  • Telescoping bar
  • Innovative, easy-to-use hinge
  • Quick-lock mechanism from 0 to 90 degrees
  • Brace can extend to ankle to help prevent migration
  • Helps reduce inventory requirements - no longer have to stock long and short versions
    • Description The cool version of the TROM provides the same easy to use protected range-of-motion and locking capabilities as the full foam TROM, but is more ideal for warmer climates. The ease of use and versatility of the Cool TROM can support a variety of protocols following major ligament surgery, meniscal repairs, patella realignment, regenerative chondroplasty and stable femoral fractures. Click here to view more on this featured product.
    Info DJO Incorporated
    Customer Service: (888) 624-5450
    Web site: http://www.djortho.com/

    Related medicine products :

    1. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
    2. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Straight)
    3. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 90)
    4. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 135)
    5. Spanish Near Point Card
    6. Lebensohn Near Point Chart
    7. Contemporary Near Point Card
    8. Wormington Near Point Card
    9. Near Point Card 4 1/2 to 24 PT - BC2202
    10. Near Point Diagnostic Card Set - BC11982
    11. Near Point Card/Newspaper 8 to 48 - BC2203
    Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 1Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 2Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 3Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 4Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 1Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 2Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 3Osseon Receives CE Mark 57784 1Osseon Receives CE Mark 57784 2